证券日报网讯 10月13日晚间，迈威生物发布公告称，近日，公司收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，注射用7MW4911的临床试验获得批准。 （文章来源：证券日报） ...

Core Viewpoint - Sanofi announced a dividend of $8.8756 million from its stake in Numab Therapeutics, which will positively impact the company's financial performance in 2025 [2] Group 1 - The company holds a 5.48% stake in Numab Therapeutics [2] - The dividend received will be accounted for in the company's 2025 financial results [2] - The dividend is expected to have a positive effect on the company's operating performance for the fiscal year 2025 [2]

Group 1: Capital Market Overview - As of the end of August, Yunnan Province has 39 listed companies, including 15 on the Shanghai Stock Exchange, 22 on the Shenzhen Stock Exchange, and 2 on the Beijing Stock Exchange, with a total share capital of 69.381 billion shares and a total market value of 867.224 billion yuan [1] - There are 10 companies in the province that are in the process of preparing for listing [1] Group 2: Financing Situation - By the end of August, 4 listed companies in Yunnan announced refinancing plans, and 2 companies are undergoing major asset restructuring [2] - In the New Third Board market, 1 company was delisted in August, leaving a total of 45 companies listed, including 14 in the innovation layer and 31 in the basic layer [2] Group 3: Bond Issuance and Financing - In August, Yunnan enterprises issued 1 new corporate bond through the exchange market, amounting to 1 billion yuan, bringing the total number of corporate bonds issued this year to 24, totaling 20.962 billion yuan [5] - The total outstanding corporate bonds in the region is 119, amounting to 88.488 billion yuan, and there are 31 outstanding asset-backed securities totaling 6.661 billion yuan [5] Group 4: Securities and Futures Market - The trading volume in the Yunnan securities market in August was 761.351 billion yuan, with stock trading accounting for 474.561 billion yuan and public fund trading at 25.091 billion yuan [6] - The total trading volume for the year in the securities market reached 4,495.956 billion yuan, with customer assets amounting to 567.633 billion yuan [6] - In the futures market, the trading volume in August was 314.75 billion yuan, with a total of 24,616.7 billion yuan for the year [6] Group 5: Private Investment Funds - As of the end of August, there are 61 registered private fund managers in Yunnan, with 152 funds filed and a total management scale of 97.245 billion yuan [7]

格隆汇10月13日丨迈威生物(688062.SH)公布，公司收到国家药品监督管理局核准签发的《药物临床试 验批准通知书》，注射用7MW4911的临床试验获得批准。7MW4911采用高度工程化设计，整合三大核 心元件：具有快速内化特性及跨物种（人/猴）中等亲和力的CDH17高特异性单抗Mab0727、新型可裂 解连接子、以及为克服多药耐药机制设计的专有DNA拓扑异构酶I抑制剂MF-6载荷。MF-6通过卓越的 血浆稳定性、可控的药物释放及强效旁观者效应，显著增强抗肿瘤活性。 ...

证券日报网讯 10月13日晚间，百克生物发布公告称，公司近日收到国家药品监督管理局下发的三价流 感病毒裂解疫苗（BK-01佐剂）的《药物临床试验批准通知书》。 （文章来源：证券日报） ...

Core Viewpoint - The company is currently operating normally but reported a loss for the first half of the year, with further details available in the official announcement [1] Group 1: Financial Performance - The company continues to experience losses in its semi-annual performance, with specifics to be detailed in the upcoming regular reports [1] - There is no risk of being classified as ST (Special Treatment) under the Shenzhen Stock Exchange's GEM listing rules [1] Group 2: Future Plans - The company is committed to advancing the market launch and sales of its injectable Epinavirin to increase market share [1] - There is a focus on expanding the pipeline for innovative drug development, with plans to increase investment in this area to prepare for future growth [1]

艾米森成立于2015年，专注于高发病率、高死亡率癌症的早期检测。公司依托自主研发的甲基化检测技术，构建了覆盖多种癌症的早筛产品管线。通过涵 盖主要癌症类型(包括结直肠癌、肝癌、食道癌)的已获批及在研产品的全谱系产品组合，并进一步扩展至尿路上皮癌、胃癌、肺癌、妇科癌等癌症领域， 也在积极扩展泛癌种检测产品管线(目前正在开发1款五种消化系统癌症联合检测试剂、1款六种高发癌症联合检测试剂、1款十二种癌症联合检测试剂)。 九月底，港交所上市申请名单上，出现3家光谷3551人才企业的身影。 9月29日，武汉聚芯微电子股份有限公司（以下简称"聚芯微电子"）和武汉艾米森生命科技股份有限公司（以下简称"艾米森"）的上市申请材料获港交所 受理并披露；次日，武汉滨会生物科技股份有限公司（以下简称"滨会生物"）也正式递交招股书。值得注意的是，聚芯微电子、艾米森曾获得光谷人才基 金投资。 聚芯微电子成立于2016年，从压力传感器起步，现已发展成为智能感知、机器视觉及影像技术解决方案的提供商。其产品线涵盖光学传感器、3D dToF及 iToF图像传感器、智能音频功放等，被广泛应用于移动智能设备、物联网等消费电子领域，并正加速向机器人、 ...

Macroeconomic Dynamics - Domestic gasoline and diesel prices will be reduced by 70 yuan and 75 yuan per ton respectively starting from October 13, 2023, due to the decline in international oil prices, resulting in a decrease of 0.06 yuan per liter for 92 and 95 gasoline and 0 diesel [2] - In the first three quarters, China's exports of high-tech products reached 3.75 trillion yuan, an increase of 11.9%, contributing over 30% to the overall export growth [5] International Relations - The Chinese Foreign Ministry criticized the U.S. for threatening to impose 100% tariffs on Chinese goods in retaliation for China's rare earth export controls, emphasizing that this approach is not the correct way to engage with China [3] - The Chinese Foreign Ministry clarified that recent export control measures on rare earths are unrelated to Pakistan's cooperation with the U.S. and are part of China's legal framework to enhance its export control system [4] Financial Institutions - UBS indicated that if the MSCI China Index drops to 74, it will find strong support, with investors likely to buy on dips, as the index has risen 36% since April [7] - New China Life Insurance expects a net profit increase of 45% to 65% year-on-year for the first three quarters of 2025, driven by reforms and improved asset allocation [9] - Everbright Bank plans to grant a comprehensive credit limit of 29 billion yuan to CITIC Financial Asset Management, constituting a related party transaction [10] - Bank of America raised its gold price forecast for next year to $5,000 per ounce [11] Market Data - The Shanghai Composite Index fell by 0.19%, with sectors like rare earth permanent magnets and gold showing strength, while over 3,600 stocks declined [12] - The financing balance in the two markets decreased by 34.95 billion yuan as of October 10, 2023 [13] - The Hong Kong Hang Seng Index dropped by 1.52%, with significant movements in the gold and semiconductor sectors [14] Company Dynamics - Microsoft will stop providing security updates and technical support for Windows 10 starting October 14, 2023, urging users to upgrade to Windows 11 [16] - Boehringer Ingelheim announced the launch of local production for its diabetes medication in China, enhancing supply stability in the market [17] - Meituan introduced a "full refund for side effects" feature for certain medications, allowing users to return products if they experience adverse effects within 21 days [18]

7MW4911是基于公司自主知识产权的IDDC™抗体偶联技术平台开发的靶向钙黏蛋白17(CDH17)的创新 抗体偶联药物(ADC)。CDH17作为经泛癌种多组学验证的潜力治疗靶点，在正常组织中局限于肠上皮基 底外侧膜表达，而在结直肠癌、胃癌及胰腺癌等消化道恶性肿瘤中呈现显著过表达，其异常高表达与肿 瘤侵袭转移及不良预后密切相关，为精准干预提供了理想靶点。 智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，注射用7MW4911的临床试验获得批准。 ...

Core Viewpoint - The announcement indicates that Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its innovative antibody-drug conjugate (ADC) 7MW4911, targeting CDH17, a promising therapeutic target in various cancers [1] Company Summary - Maiwei Biotech has developed 7MW4911 based on its proprietary IDDC antibody conjugation technology platform [1] - The ADC targets calcium adhesion protein 17 (CDH17), which is significantly overexpressed in colorectal cancer, gastric cancer, and pancreatic cancer, making it an ideal target for precise intervention [1] Industry Summary - CDH17 has been validated as a potential therapeutic target through multi-omics studies across various cancer types, indicating its relevance in cancer treatment [1] - The abnormal high expression of CDH17 is closely associated with tumor invasion, metastasis, and poor prognosis, highlighting its importance in oncology [1]